Allergy Therapeutics Plans Potential Equity Raise Ahead of Hong Kong Listing

Allergy Therapeutics ( (GB:AGY) ) just unveiled an update.

Allergy Therapeutics has announced plans for a potential equity raise by issuing new shares to facilitate its dual listing on the Hong Kong Stock Exchange, expected in the first half of 2026. The company is seeking shareholder approval to issue up to 610 million new shares, which will support its strategy of developing treatments for grass and peanut allergies and address general corporate needs. The outcome of the equity raise remains uncertain, as no agreements with investors have been finalized.

The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.

Spark’s Take on GB:AGY Stock

According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.

The stock score is primarily impacted by the company’s weak financial performance and valuation concerns, which are somewhat balanced by positive technical indicators and promising corporate events. The financial instability remains a significant risk, although recent product developments offer potential upside.

To see Spark’s full report on GB:AGY stock, click here.

More about Allergy Therapeutics

Allergy Therapeutics is a UK-based international commercial biotechnology company specializing in the treatment and diagnosis of allergic disorders. The company focuses on aluminium-free immunotherapy vaccines that have the potential to cure diseases. It operates in nine major European countries and has distribution agreements in ten additional countries.

Average Trading Volume: 395,577

Technical Sentiment Signal: Buy

Current Market Cap: £657.1M

Find detailed analytics on AGY stock on TipRanks’ Stock Analysis page.